Table 2. Centile line crossings (at the most differential point away from an individual’s starting centile) in the validation datasets used in the study.
| Type | Dataset | Group | Total centile line crossings | Upward centile lins crossings | Downward centile line crossings | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | >2 | 0 | 1 | 2 | >2 | 0 | 1 | 2 | >2 | |||
| Healthy | WALTHAM/RC colonies | WALTHAM Population | 37 (10%) | 174 (48%) | 133 (37%) | 16 (4%) | 16 (4%) | 66 (18%) | 53 (15%) | 5 (1%) | 21 (6%) | 108 (30%) | 80 (22%) | 11 (3%) |
| RC Population | 0 (0%) | 11 (92%) | 1 (8%) | 0 (0%) | 0 (0%) | 2 (17%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (75%) | 1 (8%) | 0 (0%) | ||
| Vitamin A | N/A | 1 (2%) | 19 (40%) | 20 (42%) | 8 (17%) | 0 (0%) | 12 (25%) | 7 (15%) | 1 (2%) | 1 (2%) | 7 (15%) | 13 (27%) | 7 (15%) | |
| Energy intake study | Optimal feeding | 0 (0%) | 2 (33%) | 2 (33%) | 2 (33%) | 0 (0%) | 1 (17%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (17%) | 2 (33%) | 2 (33%) | |
| Abnormal body condition | Energy intake study | Supplemental feeding | 0 (0%) | 1 (12%) | 3 (38%) | 4 (50%) | 0 (0%) | 1 (12%) | 1 (12%) | 1 (12%) | 0 (0%) | 0 (0%) | 2 (25%) | 3 (38%) |
| Restricted feeding | 0 (0%) | 1 (12%) | 6 (75%) | 1 (12%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (12%) | 6 (100%) | 1 (12%) | ||
| Body condition veterinary records | Overweight | 13199 (9%) | 45916 (31%) | 45578 (31%) | 44111 (30%) | 8394 (6%) | 29702 (20%) | 35067 (24%) | 39293 (26%) | 4805 (3%) | 16214 (11%) | 10511 (7%) | 4818 (3%) | |
| Obesity | 644 (8%) | 1,946 (24%) | 2,327 (28%) | 3,291 (40%) | 438 (5%) | 1358 (17%) | 1879 (23%) | 3010 (37%) | 206 (3%) | 588 (7%) | 448 (5%) | 281 (3%) | ||
| Underweight | 2,343 (13%) | 6,949 (38%) | 5,499 (30%) | 3,456 (19%) | 1033 (6%) | 2865 (16%) | 2258 (12%) | 1691 (9%) | 1310 (7%) | 4084 (22%) | 3241 (18%) | 1765 (10%) | ||
| Unhealthy | BANFIELD® retarded growth conditions | Dwarfism | 8 (28%) | 9 (31%) | 11 (38%) | 1 (3%) | 2 (7%) | 4 (14%) | 4 (14%) | 1 (3%) | 6 (21%) | 5 (17%) | 7 (24%) | 0 (0%) |
| Nutritional Osteodystrophy | 7 (29%) | 7 (29%) | 4 (17%) | 6 (25%) | 4 (17%) | 4 (17%) | 2 (8%) | 5 (21%) | 3 (13%) | 3 (13%) | 2 (8%) | 1 (4%) | ||
| PRAA/VRA | 3 (7%) | 21 (50%) | 12 (29%) | 6 (14%) | 1 (2%) | 11 (26%) | 3 (7%) | 4 (10%) | 2 (5%) | 10 (24%) | 9 (21%) | 2 (5%) | ||
| Portosystemic Shunt | 158 (14%) | 541 (48%) | 313 (28%) | 104 (9%) | 62 (6%) | 236 (21%) | 161 (14%) | 63 (6%) | 96 (9%) | 305 (27%) | 152 (14%) | 41 (4%) | ||
| Hepatic Encephalopathy | 19 (11%) | 85 (51%) | 38 (23%) | 24 (14%) | 5 (3%) | 41 (25%) | 19 (11%) | 9 (5%) | 14 (8%) | 44 (27%) | 19 (11%) | 15 (9%) | ||
| Megaoesophagus | 52 (13%) | 155 (40%) | 124 (32%) | 61 (16%) | 20 (5%) | 70 (18%) | 65 (17%) | 35 (9%) | 32 (8%) | 85 (22%) | 59 (15%) | 26 (7%) | ||
| BANFIELD® accelerated growth conditions | Hypertrophic osteodystrophy | 23 (9%) | 94 (36%) | 80 (31%) | 65 (25%) | 11 (4%) | 43 (16%) | 45 (17%) | 44 (17%) | 12 (5%) | 51 (19%) | 35 (13%) | 21 (8%) | |
| Hip Dysplasia, Medical | 932 (10%) | 3,260 (36%) | 2,700 (30%) | 2,195 (24%) | 444 (5%) | 1768 (20%) | 1628 (18%) | 1668 (18%) | 488 (5%) | 1492 (16%) | 1072 (12%) | 527 (6%) | ||
| Hip Dysplasia, Surgical | 130 (10%) | 450 (36%) | 392 (31%) | 287 (23%) | 53 (4%) | 250 (20%) | 231 (18%) | 220 (17%) | 77 (6%) | 200 (16%) | 161 (13%) | 67 (5%) | ||
| Osteochondritis dissecans | 94 (10%) | 315 (34%) | 285 (31%) | 226 (25%) | 41 (4%) | 171 (19%) | 170 (18%) | 170 (18%) | 53 (6%) | 144 (16%) | 115 (13%) | 56 (6%) | ||
| Anconeal and coronoid process | 23 (8%) | 109 (38%) | 89 (31%) | 68 (24%) | 13 (4%) | 61 (21%) | 53 (18%) | 51 (18%) | 10 (3%) | 48 (17%) | 36 (12%) | 17 (6%) | ||
RC: ROYAL CANIN; WALTHAM: Waltham Petcare Science Institute; N/A: not applicable; VRA: vascular ring anomaly; PRAA: persistent right aortic arch.